SPPAM
ALXN

Summit Partners Public Asset Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Summit Partners Public Asset Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-217,900
Closed -$30.3M – 104
2018
Q3 		$30.3M Buy
217,900
+137,900
+172% +$17.3M 2.05% 9
2018
Q2 		$9.93M Buy
+80,000
New +$9.35M 1.1% 28

Other funds holding ALXN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Summit Partners Public Asset Management's ALXN Position: Q3 2019 in Review

Summit Partners Public Asset Management sold out of Alexion Pharmaceuticals (ALXN) in Q3 2019, closing a stake of 85,000 shares — an estimated $11.1M sold.

Summit Partners Public Asset Management first reported a position in ALXN in Q1 2019 and held it in 2 quarters. The position peaked at $11.1M in Q2 2019. 647 funds tracked by Wall St. Rank hold ALXN as of Q3 2019.

  • Summit Partners Public Asset Management reported no remaining Alexion Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
  • Summit Partners Public Asset Management sold 85,000 Alexion Pharmaceuticals shares in Q3 2019, an estimated $11.1M.
  • Summit Partners Public Asset Management first reported a position in Alexion Pharmaceuticals in Q1 2019 and held it in 2 quarters.
  • Summit Partners Public Asset Management's Alexion Pharmaceuticals position peaked at $11.1M in Q2 2019.
  • 647 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2019.

Based on Summit Partners Public Asset Management's 13F filing for Q3 2019, filed 14 Nov 2019.